Tempus AI, Inc. (TEM)
| Market Cap | 11.56B -9.2% |
| Revenue (ttm) | 1.43B +50.4% |
| Net Income | -254.43M |
| EPS | -1.43 |
| Shares Out | 180.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,774,759 |
| Open | 69.05 |
| Previous Close | 70.69 |
| Day's Range | 63.77 - 70.90 |
| 52-Week Range | 40.77 - 104.32 |
| Beta | 3.58 |
| Analysts | Buy |
| Price Target | 63.36 (-1.06%) |
| Earnings Date | Jul 30, 2026 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $63.36, which is a decrease of -1.06% from the latest price.
News
Top Performing Leveraged/Inverse ETFs: 08/23/2026
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Tempus AI receives FDA clearance for Tempus ECG-PH
Tempus AI (TEM) announced it has received 510(k) clearance from the U.S. Food and Drug Administration, FDA, for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardi...
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an...
Tempus AI price target raised to $80 from $70 at BTIG
BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI (TEM) to $80 from $70 and keeps a Buy rating on the shares as part of a broader…
Tempus AI stock is soaring and it has Moderna to thank
Tempus AI (TEM) stock ripped higher on August 19 as third-party clinical breakthroughs triggered a technical short squeeze. As investors cheered TEM, it broke decisively above its major moving average...
‘Prepare for What’s Coming,’ Says Investor About Tempus AI Stock
Tempus AI (NASDAQ:TEM) stock is soaring about 22% on Wednesday, with Moderna’s huge melanoma win giving investors a new reason to reconsider the value of Tempus’ pending Personalis acquisition. Modern...
Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why
Tempus AI ($TEM) surged nearly 24% on Wednesday after a major Phase 3 cancer vaccine update from Merck ($MRK) and Moderna ($MRNA). The news instantly justified Tempus AI’s recent $1.5…
Tempus AI added to CellCarta’s CDx commercialization lab network
Tempus AI (TEM) announced a strategic collaboration with CellCarta, a global CRO laboratory supporting the biopharmaceutical industry. Under the agreement, CellCarta will include Tempus in its CDx Com...
CellCarta Adds Tempus to CDx Commercialization Lab Network
Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model. MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO l...
Personalis says not providing guidance or conducting earnings call
As a result of the announcement on July 20, 2026 that Personalis (PSNL) and Tempus AI (TEM) have entered into an Agreement and Plan of Merger, Personalis will no longer…
Tempus AI announces study results of PRISM2
Tempus AI (TEM) announced study results demonstrating that PRISM2, a multimodal slide-level pathology foundation model developed in collaboration with researchers from Microsoft (MSFT), can perform cl...
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating tha...
Tempus AI price target lowered to $56 from $58 at Piper Sandler
Piper Sandler lowered the firm’s price target on Tempus AI (TEM) to $56 from $58 following quarterly results. The firm keeps a Neutral rating on the shares. Published first on…
Tempus AI price target lowered to $70 from $80 at BTIG
BTIG lowered the firm’s price target on Tempus AI (TEM) to $70 from $80 and keeps a Buy rating on the shares following quarterly results. The firm notes Tempus delivered…
Tempus AI price target lowered to $56 from $64 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Tempus AI (TEM) to $56 from $64 and keeps a Buy rating on the shares. The company reported a…
Tempus AI price target lowered to $52 from $64 at BofA
BofA lowered the firm’s price target on Tempus AI (TEM) to $52 from $64 and keeps a Neutral rating on the shares. The firm updated its estimates after the company’s…
Tempus AI price target lowered to $50 from $60 at Stifel
Stifel lowered the firm’s price target on Tempus AI (TEM) to $50 from $60 and keeps a Hold rating on the shares. While the firm trimmed its target after a…
Tempus AI price target lowered to $59 from $67 at Baird
Baird lowered the firm’s price target on Tempus AI (TEM) to $59 from $67 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.
Tempus AI Earnings Call Transcript: Q2 2026
Q2 revenue grew 22% year-over-year, driven by strong Diagnostics and Data & Apps performance, with major pharma deals and FDA approvals setting up significant future revenue gains. The Personalis acquisition and new financing support continued growth and margin expansion.
Tempus AI Earnings release: Q2 2026
Tempus AI released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Tempus AI Quarterly report: Q2 2026
Tempus AI has published its Q2 2026 quarterly earnings report on July 30, 2026.
Tempus AI Slides: Q2 2026
Tempus AI has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.